Genome and Company

Genome and Company is a globally leading microbiome anti-cancer drug development company, primarily focusing on anti-cancer microbiome therapies and novel targeted immune checkpoint inhibitors. Through continuous open innovation via global external collaborations and strategic investments, the company has expanded its microbiome pipeline into the brain disease field and continues to explore the market, evolving into a fully integrated global healthcare group capable of conducting research.